市场失灵与孕产妇保健新药匮乏
Market failure and the poverty of new drugs in maternal health.
作者信息
Fisk Nicholas M, Atun Rifat
机构信息
Imperial College London, London, United Kingdom.
出版信息
PLoS Med. 2008 Jan 22;5(1):e22. doi: 10.1371/journal.pmed.0050022.
Abstract
A new survey finds that only 17 drugs are under active development for maternal health indications, which is less than 3% of the pipeline in cardiovascular health (660 drugs).
摘要
一项新调查发现，目前仅有17种药物正在积极研发用于孕产妇健康适应症，这不到心血管健康领域在研药物（660种）的3%。
相似文献
1
Market failure and the poverty of new drugs in maternal health.
PLoS Med. 2008 Jan 22;5(1):e22. doi: 10.1371/journal.pmed.0050022.
2
Biotech blockbusters consolidate markets.
Nat Biotechnol. 2006 Dec;24(12):1466. doi: 10.1038/nbt1206-1466.
3
New estimates of drug development costs.
J Health Econ. 2003 Mar;22(2):325-30. doi: 10.1016/S0167-6296(03)00002-X.
4
Costing drug development.
Nat Rev Drug Discov. 2003 Apr;2(4):247. doi: 10.1038/nrd1070.
5
Deconstructing Myogen's market cap.
Nat Biotechnol. 2006 Mar;24(3):227-8. doi: 10.1038/nbt0306-227.
6
Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
J Health Econ. 2001 Nov;20(6):1033-57. doi: 10.1016/s0167-6296(01)00108-4.
7
The price of innovation: new estimates of drug development costs.
J Health Econ. 2003 Mar;22(2):151-85. doi: 10.1016/S0167-6296(02)00126-1.
8
Risks in new drug development: approval success rates for investigational drugs.
Clin Pharmacol Ther. 2001 May;69(5):297-307. doi: 10.1067/mcp.2001.115446.
9
Cost of innovation in the pharmaceutical industry.
J Health Econ. 1991 Jul;10(2):107-42. doi: 10.1016/0167-6296(91)90001-4.
10
Therapeutic possibilities of interference RNA.
Farm Hosp. 2012 May-Jun;36(3):115-7. doi: 10.1016/j.farma.2011.09.001. Epub 2011 Dec 3.
引用本文的文献
1
Identifying and assessing the capacity and experience of trial sites in low- and middle-income countries for high-quality randomised drug trials in maternal and perinatal health.
BMJ Glob Health. 2025 Jul 27;10(7):e018063. doi: 10.1136/bmjgh-2024-018063.
2
The drug drought in maternal health: an ongoing predicament.
Lancet Glob Health. 2024 Jul;12(7):e1174-e1183. doi: 10.1016/S2214-109X(24)00144-X.
3
Factors influencing the participation of pregnant and lactating women in clinical trials: A mixed-methods systematic review.
PLoS Med. 2024 May 30;21(5):e1004405. doi: 10.1371/journal.pmed.1004405. eCollection 2024 May.
4
Actively Targeted Nanomedicines: A New Perspective for the Treatment of Pregnancy-Related Diseases.
Reprod Sci. 2024 Sep;31(9):2560-2575. doi: 10.1007/s43032-024-01520-z. Epub 2024 Mar 29.
5
How the structural determinants of health inequities impact access to prescription medication for pregnant women in Australia: a narrative review.
Lancet Reg Health West Pac. 2023 Oct 10;42:100934. doi: 10.1016/j.lanwpc.2023.100934. eCollection 2024 Jan.
6
Maternal-fetal cross-talk via the placenta: influence on offspring development and metabolism.
Development. 2023 Oct 15;150(20). doi: 10.1242/dev.202088. Epub 2023 Oct 13.
7
New medicines for spontaneous preterm birth prevention and preterm labour management: landscape analysis of the medicine development pipeline.
BMC Pregnancy Childbirth. 2023 Jul 18;23(1):525. doi: 10.1186/s12884-023-05842-9.
8
Rational Design of Nanomedicine for Placental Disorders: Birthing a New Era in Women's Reproductive Health.
Small. 2024 Oct;20(41):e2300852. doi: 10.1002/smll.202300852. Epub 2023 May 16.
9
Target product profiles for novel medicines to prevent and treat preeclampsia: An expert consensus.
PLOS Glob Public Health. 2022 Nov 18;2(11):e0001260. doi: 10.1371/journal.pgph.0001260. eCollection 2022.
10
Placenta-Targeted Nanoparticles Loaded with PFKFB3 Overexpression Plasmids Enhance Angiogenesis and Placental Function.
Bioengineering (Basel). 2022 Nov 4;9(11):652. doi: 10.3390/bioengineering9110652.
本文引用的文献
1
Research challenges to improve maternal and child survival.
Lancet. 2007 Apr 14;369(9569):1240-1243. doi: 10.1016/S0140-6736(07)60574-1.
2
Births: preliminary data for 2005.
Natl Vital Stat Rep. 2006 Dec 28;55(11):1-18.
3
The demise of the blockbuster?
N Engl J Med. 2007 Mar 29;356(13):1292-3. doi: 10.1056/NEJMp078020.
4
2006 drug approvals: finding the niche.
Nat Rev Drug Discov. 2007 Feb;6(2):99-101. doi: 10.1038/nrd2247.
5
The epidemiology of ALS and the role of population-based registries.
Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):1150-7. doi: 10.1016/j.bbadis.2006.09.008. Epub 2006 Sep 29.
6
Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
Eur J Clin Pharmacol. 2006 Nov;62(11):947-52. doi: 10.1007/s00228-006-0193-0. Epub 2006 Oct 5.
7
Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness.
Health Econ. 2007 May;16(5):491-511. doi: 10.1002/hec.1176.
8
Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002.
J Clin Pharmacol. 2006 Sep;46(9):1038-43. doi: 10.1177/0091270006290509.
9
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.
Lancet. 2006 May 27;367(9524):1747-57. doi: 10.1016/S0140-6736(06)68770-9.
10
Stillbirth rates: delivering estimates in 190 countries.
Lancet. 2006 May 6;367(9521):1487-94. doi: 10.1016/S0140-6736(06)68586-3.
Zotero 插件